New pill shows promise in early breast cancer trial

NCT ID NCT05654532

Ongoing Disease control Sponsor: Accutar Biotechnology Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called AC699 in 100 adults with a common type of advanced breast cancer (ER+/HER2-). The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors. Participants must have already tried standard treatments without success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AC699 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced ER+/HER2- breast cancer who have run out of standard options.
What could go wrong: This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects. Only 100 people are enrolled, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Site 01

Nashville, Tennessee, 37203, United States
Site 02

Sarasota, Florida, 34232, United States
Site 03

Houston, Texas, 77030, United States
Site 04

Vancouver, Washington, 98684, United States
Site 05

Norfolk, Virginia, 23502, United States
Site 06

Rockville, Maryland, 21044, United States
Site 07

Orlando, Florida, 32746, United States
Site 08

Denver, Colorado, 80218, United States
Site 09

San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.